Agilent Raises FY26 Revenue Outlook to $7.3B–$7.5B After Solid 7% Q1 Growth
Agilent reported Q1 FY2026 revenue of $1.80 billion, a 7.0% increase year-on-year, and non-GAAP EPS of $1.36, up 4%. It raised full-year fiscal 2026 revenue guidance to $7.3 billion–$7.5 billion (5.5%–7.5% growth) and non-GAAP EPS guidance to $5.90–$6.04, with Q2 revenue seen at $1.79 billion–$1.82 billion (7%–9%).
1. First-Quarter Fiscal Year 2026 Results
Agilent recorded Q1 FY2026 revenue of $1.80 billion, a 7.0% increase reported and 4.4% core growth year-on-year. GAAP net income was $305 million, or $1.07 per share, while non-GAAP net income reached $386 million, or $1.36 per share.
2. Raised Full-Year and Q2 Guidance
Agilent raised its full-year fiscal 2026 revenue outlook to $7.3 billion–$7.5 billion, reflecting 5.5%–7.5% reported growth and 4%–6% core growth, and increased non-GAAP EPS guidance to $5.90–$6.04. For Q2, revenue is projected between $1.79 billion and $1.82 billion (7%–9% reported growth) with non-GAAP EPS of $1.39–$1.42.
3. Segment Revenue and Margins
Life Sciences & Diagnostics delivered $679 million in Q1 revenue, up 5% reported and 3% core, with a 16.0% operating margin. CrossLab generated $758 million, up 9% reported and 6% core, at a 31.6% margin, while Applied Markets posted $361 million, up 7% reported and 4% core, at a 25.8% margin.
4. GAAP vs Non-GAAP Income Trends
GAAP net income fell 4% year-on-year to $305 million (EPS $1.07), while non-GAAP EPS rose 4% to $1.36, driven by core business expansion and favorable currency after excluding one-time impacts.